SCHEMBL2398405

SCHEMBL2398405

Cc1cc(OCCCC2CCN(c3nc(C(C)(C)C)no3)CC2)ccc1C(=O)N[C@H]1CCOC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.42
RAB9A P51151 3/20 0.39
HPGDS O60760 1/20 0.38
KMT2A Q03164 1/20 0.37
ABL1 P00519 1/20 0.36
BMPR1B O00238 1/20 0.36
BMPR1A P36894 1/20 0.36
TGFBR1 P36897 1/20 0.36
ACVRL1 P37023 1/20 0.36
ACVR1 Q04771 1/20 0.36
GPR84 Q9NQS5 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
TTK P33981 2/20 0.35
IDH1 O75874 1/20 0.35
NPC1 O15118 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
GABRA5 P31644 1/20 0.35
FASN P49327 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394389 1.00 GPR119 (0.42) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2394392 1.00 GPR119 (0.42) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2394333 0.95 GPR119 (0.44) GPR119RAB9AABL1BMPR1BBMPR1A
SCHEMBL2395228 0.90 GPR119 (0.42) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2395225 0.90 GPR119 (0.42) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2215217 0.90 GPR119 (0.42) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2215219 0.90 GPR119 (0.42) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2392621 0.89 GPR119 (0.47) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2392624 0.89 GPR119 (0.47) GPR119RAB9AHPGDSKMT2AABL1
SCHEMBL2398765 0.87 GPR119 (0.38) GPR119RAB9AGPR84NPC1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321308-B9 PIPERIDINE GPCR AGONISTS PROSIDION LTD (GB) 2012-08-08 EP claimed
EP-2321308-B1 PIPERIDINE GPCR AGONISTS PROSIDION LTD (GB) 2012-05-09 EP claimed
EP-2321308-B9 PIPERIDINE GPCR AGONISTS PROSIDION LTD (GB) 2012-08-08 EP disclosed
EP-2321308-B1 PIPERIDINE GPCR AGONISTS PROSIDION LTD (GB) 2012-05-09 EP disclosed
US-20110230507-A1 Piperidine GPCR Agonists PROSIDION LIMITED (GB) 2011-09-22 US disclosed
US-20110230507-A1 Piperidine GPCR Agonists PROSIDION LIMITED (GB) 2011-09-22 US disclosed
US-20110230507-A1 Piperidine GPCR Agonists PROSIDION LIMITED (GB) 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230507-A1 Piperidine GPCR Agonists GPR119, GPR27, GLP1R GPR119 1/4885RAB9A 647/4885HPGDS 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.